Post on 18-Mar-2020
Pharmacy and Therapeutics Committee-approvedTherapeutic Interchanges
Therapeutic Interchange Revision Date
Alpha Blockers 08/11
Alpha Reductase Inhibitors 05/16
ACE Inhibitors 08/11
Angiotensin Receptor Blockers 08/11
Buprenorphine 09/11
Calcium Channel Blockers (DHP) 08/11
Carbapenems 07/11
Cardioselective Beta Blockers 08/11
Cephalosporins 09/11
Corticosteroids, Inhaled 06/16
Corticosteroids, Intranasal 08/11
Fluoroquinolones 01/13
Glitazones 08/11
Histamine Receptor Antagonists (H2RAs) 08/11
Inhaled Anticholinergics 05/16
Insulin Analogs 05/16
IV to PO conversions 05/16
Leukotriene Receptor Antagonists 08/11
Levalbuterol 12/13
Miscellaneous Antidepressants 05/16
Miscellaneous CNS Stimulants 05/16
Nitroglycerin Sublingual 05/16
Non-benzodiazepine Hypnotics 08/11
Non-sedating Antihistamines 08/11
Ophthalmic Preparations 08/11
Phosphate Binders 01/13
Proton Pump Inhbitors 08/11
Statins 08/11
All conversions unless noted otherwise are for adult patients with normal renal and/or hepatic
function. Please consult additional references when these clinical situations do not apply.
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Alpha Blockers
Generic Name Brand Name
Terazosin Hytrin® 1 2 5 10 20
Doxazosin Cardura® 1 2 4 8 16
Tamsulosin Flomax® 0.4 0.8 N/A N/A N/A
Alfuzosin UroXatral® 10 10 N/A N/A N/A
*Formulary agents in bold.
Notes:
Prazosin is not included in this therapeutic interchange.
Dose Equivalents (mg/day)
Doxazosin and terazosin are therapeutically equivalent for the treatment of hypertension and benign
prostatic hypertrophy (BPH).
Alfuzosin and tamsulosin are therapeutically equivalent for the treatment of BPH and are the preferred
agents in patients who are unable to tolerate the cardiovascular adverse effects from other alpha blockers.
Document created: 08/11.
Revised: None
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Alpha Reductase Inhibitors
Generic Name Brand Name
Finasteride Proscar®
Dutasteride Avodart®
*Formulary agents in bold.
Dose Equivalents (mg/day)
5 mg once daily
0.5 mg once daily
Document created: 05/16.
Revised: None
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: ACE Inhibitors
Generic Name Brand Name
Short-acting
Captopril Capoten® 75 150 300 450
Intermediate-acting
Benazepril Lotensin® 5 10 20 40
Enalapril Vasotec® 5 10 20 40
Moexipril Univasc® 7.5 15 22.5 30
Quinapril Accupril® 5 10 20 40
Ramipril Altace® 2.5 5 10 20
Long-acting
Lisinopril Prinivil® 5 10 20 40
Fosinopril Monopril® 5 10 20 40
Perindopril Aceon® 4 8 12 16
Trandolapril Mavik® 1 2 4 8
*Formulary agents in bold.
Notes:
Captopril is short-acting and should be dosed 2-3 times daily.
Lisinopril is long-acting and should be dosed once daily.
Dose Equivalents (mg/day)
Enalapril and benazepril are intermediate-acting and should be dosed 1-2 times daily. Enalapril is the
preferred intermediate-acting ACE inhibitor. Benazepril is available for continuation of outpatient therapy.
Document created: 12/03.
Revised: 08/11.
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Angiotensin Receptor Blockers
Generic Name Brand Name
Losartan Cozaar® 25 50 100 100
Candesartan Atacand® 4 8 16 32
Eprosartan Teveten® 200 400 600 800
Irbesartan Avapro® 75 150 300 300
Olmesartan Benicar® 5 10 20 40
Telmisartan Micardis® 20 40 80 80
Valsartan Diovan® 40 80 160 320
*Formulary agent in bold.
Dose Equivalents (mg/day)
Document created: 08/11.
Revised: None
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Buprenorphine Sublingual
Generic Name Brand Name
Buprenorphine Subutex® 8 16 24
Buprenorphine/naloxone Suboxone® 8/2 16/4 24/6
*Formulary agent in bold.
Notes:
Dose Equivalents (mg/day)
Suboxone® strength expressed as buprenorphine/naloxone which are available as 2 mg/0.5 mg and 8 mg/2
mg sublingual tablets and film.
Document created: 09/11.
Revised: None
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Calcium Channel Blockers (Dihydropyridines)
Generic Name Brand Name
Amlodipine Norvasc® 2.5 5 10
Nifedipine, extended release Procardia XL® 30 60 90
Felodipine, extended release Plendil® 2.5 5 10
Isradipine, immediate release DynaCirc® 5 10 20
Isradipine, controlled release DynaCirc CR® 5 10 20
Nicardipine, immediate release Cardene® 60 90 120
Nicardipine, controlled release Cardene CR® 60 90 120
Nisoldipine, extended release Sular® 17 25.5 34
*Formulary agents in bold.
Notes:
Nimodipine (Nimotop®) is not subject to therapeutic interchange.
Dose Equivalents (mg/day)
Amlodipine is the preferred dihydropyridine CCB. Nifedipine, extended release is available for continuation
of outpatient therapy.
Document created: 08/11.
Revised: None
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Carbapenems
Generic Name Brand Name
Meropenem Merrem® 2000 3000
Doripenem Doribax® 1500 3000
Imipenem/cilastatin Primaxin® 2000 3000
*Formulary agents in bold.
Notes:
Dose Equivalents (mg/day)
The preferred dosing for the treatment of infections caused by multi-resistant gram negative bacilli or
empiric therapy is meropenem 500 mg every 6 hours. Please refer to the Carbapenem Guidelines for Use
for further details.
Document created: 07/11.
Revised: None
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Cardioselective Beta Blockers
Generic Name Brand Name
Atenolol Tenormin® 25 50 100 N/A
Metoprolol Toprol® 50 100 200 400
Betaxolol Kerlone® 10 20 N/A N/A
Bisoprolol Zebeta® 5 10 20 N/A
Nebivolol Bystolic® 5 10 20 40
*Formulary agents in bold.
Notes:
Dose Equivalents (mg/day)
Metoprolol is the preferred cardioselective beta blocker. Atenolol is available for continuation of outpatient
therapy.
Document created: 08/11.
Revised: None
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Cephalosporins
Generic Name Brand Name
Ceftriaxone Rocephin® 1000 2000 3000 4000
Cefotaxime Claforan® 3000 6000 9000 12000
*Formulary agent in bold.
Notes:
Dose Equivalents (mg/day)
Ceftriaxone is the preferred third generation cephalosporin in adult patients. Cefotaxime is available for use
in neonates and for orders written by Infectious Diseases faculty.
Usual adult dosing for ceftriaxone is 1-2 gm every 12-24 hours (max: 4 gm/day), usual adult dosing for
cefotaxime is 1-2 gm every 6-8 hours (max: 12 gm/day).
Document created: 09/11.
Revised: None
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Corticosteroids, Inhaled
Generic Name Brand Name
Beclomethasone
dipropionate QVAR® 80 mcg 1 2 4 6 8
Budesonide Pulmicort® 180 mcg 1 2 to 3 4 to 5 6 7+
Fluticasone Arnuity® Ellipta 100 mcg
Fluticasone Arnuity® Ellipta 200 mcg
Fluticasone Flovent® HFA 44 mcg 1 to 3 4 to 6 7 to 8 9 to 10 11+
Fluticasone Flovent® HFA 110 mcg 1 2 3 4 5+
Fluticasone Flovent® HFA 220 mcg N/A 1 N/A 2 3+
Fluticasone Flovent® Diskus 50 mcg 1 to 3 4 to 6 7 to 8 9 to 10 11+
Fluticasone Flovent® Diskus 100 mcg 1 2 to 3 4 5 6+
Fluticasone Flovent® Diskus 250 mcg N/A 1 N/A 2 3+
Mometasone Asmanex® 220 mcg N/A 1 2 3 4+
*Formulary agent in bold.
Generic Name Brand Name
Budesonide/formoterol Symbicort® 80/4.5
Budesonide/formoterol Symbicort® 160/4.5
Mometasone/formoterol Dulera® 100/5
Mometasone/formoterol Dulera® 200/5
Fluticasone/vilanterol Breo® Ellipta 100/25
Fluticasone/vilanterol Breo® Ellipta 200/25
Fluticasone/salmeterol Advair® HFA 45/21
Fluticasone/salmeterol Advair® HFA 115/21
Fluticasone/salmeterol Advair® HFA 230/21
Fluticasone/salmeterol Advair® Diskus 100/50
Fluticasone/salmeterol Advair® Diskus 250/50
Fluticasone/salmeterol Advair® Diskus 500/50
*Formulary agent in bold.
Notes:
Breo® Ellipta (fluticasone/vilanterol) is indicated for asthma at one inhalation (100 mcg/25 mcg) once daily with
maximum dosing of one inhalation (200 mcg/25 mcg) once daily and for COPD at one inhalation (100 mcg/25 mcg) once
daily.
N/A
N/A 1 inhalation twice daily
1 inhalation twice daily
N/A
1 inhalation twice daily N/A
N/A
N/A
N/A
N/A 1 inhalation once daily
1 inhalation once daily N/A
2 puffs twice daily
N/A
2 puffs twice daily
2 puffs twice daily
2 puffs twice daily
2 puffs twice daily
N/A
2 puffs twice daily
N/A
2 puffs twice daily
Dose Equivalents (puffs per day)
Dose Equivalents (puffs per day)
1 inhalation once daily
N/A
2 inhalations once daily
N/A
Document created: 01/08.
Revised: 01/17.
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Corticosteroids, Intranasal
Generic Name Brand Name Dose Equivalents
Fluticasone propionate Flonase® 2 sprays in each nostril daily
Beclomethasone Beconase AQ® 1 to 2 sprays in each nostril twice daily
Budesonide Rhinocort Aqua® 1 spray in each nostril daily
Ciclesonide Omnaris® 2 sprays in each nostril daily
Flunisolide Nasarel® 2 sprays in each nostril 2 to 3 times daily
Fluticasone furoate Veramyst® 2 sprays in each nostril daily
Mometasone Nasonex® 2 sprays in each nostril daily
Triamcinolone Nasacort AQ® 1 to 2 sprays in each nostril daily
*Formulary agent in bold.
Document created: 01/08.
Revised: 08/11.
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Fluoroquinolones
Generic Name Brand Name
Intravenous Oral
Ciprofloxacin Cipro®
Mild to moderate infections: 200
to 400 mg every 12 hours
Severe infections: 400 mg every
8 to 12 hours
Mild to moderate infections: 250
to 500 mg every 12 hours
Severe infections: 500 to 750 mg
every 8 to 12 hours
Moxifloxacin Avelox® 400 mg every 24 hours 400 mg every 24 hours
Levofloxacin Levaquin®
Mild to moderate infections: 250
to 500 mg every 24 hours
Severe infections: 500 to 750 mg
every 24 hours
Mild to moderate infections: 250
to 500 mg every 24 hours
Severe infections: 500 to 750 mg
every 24 hours
Ofloxacin Floxin® N/A 200 to 400 mg every 12 hours
Norfloxacin Noroxin® N/A 400 mg every 12 hours
Gemifloxacin Factive® N/A 320 mg every 24 hours
*Formulary agents in bold.
Note:
Moxifloxacin should not be used for genitourinary infections and gram-negative bacteremias.
Dose Equivalents (mg/day)
Document created: 05/06.
Revised: 01/13.
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Thiazolidinediones (Glitazones)
Generic Name Brand Name
Pioglitazone Actos® 15 30 45
Rosiglitazone Avandia® 2 4 8
*Formulary agent in bold.
Dose Equivalents (mg/day)
Document created: 06/07.
Revised: 08/11.
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Histamine Receptor Blockers
Generic Name Brand Name
Famotidine, oral Pepcid® 20 40
Cimetidine Tagamet® N/A 600 to 1200
Nizatidine Axid® 150 300
Ranitidine Zantac® 150 300
Famotidine, injection Pepcid IV® 20 40
Cimetidine Tagamet IV® N/A 900 to 1200
Ranitidine Zantac IV® 50 to 100 150 to 200
*Formulary agent in bold.
Dose Equivalents (mg/day)
By declaration of the P&T Committee, the H2RAs are subject to automatic IV to PO interchange.
Please refer to the Intravenous to Oral Medication Conversion Program for further details.
Document created: 02/08.
Revised: 08/11.
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Inhaled Anticholinergics
Generic Name Brand Name Dose Equivalents
Albuterol MDI Ventolin® 1-2 inhalations every 4-6 hours
Albuterol nebulization solution Ventolin® 1 vial three to four times per day
Ipratropium nebulization solution Atrovent® 1 vial three to four times per day
Ipratropium/albuterol nebulization solution DuoNeb® 1 vial four times per day
Ipratropium/albuterol MDI Combivent® 2 inhalations four to six times per day
Ipratropium MDI Atrovent® 2 inhalations four to six times per day
Tiotropium inhalation Spiriva® Respimat 2 inhalations (2.5 mcg each) once daily
Tiotropium inhalation Spiriva® Handihaler 1 capsule once daily
Aclidinium inhalation Tudorza® 1 inhalation twice daily
Umeclidinium inhalation Incruse® 1 inhalation once daily
*Formulary agents in bold.
Notes:
DuoNeb® contains ipratropium 0.5 mg and albuterol 3 mg in each 3 mL unit-dose vial.
Spiriva® HandiHaler is to be used for administration of tiotropium which is dosed at 2 inhalations of a single 18
mcg capsule once daily.
Combivent® Respimat inhaler contains ipratropium 20 mcg and albuterol 100 mcg in each inhalation (120
inhalations per cartridge).
Combivent® Respimat inhalers are not available for inpatient use at UPHSM. Non-ventilated patients may be
switched to umeclidinium inhalation with or without an albuterol MDI (albuterol must be ordered separately) or
to ipratropium/albuterol (DuoNeb®) nebulization solution. Ventilated patients may be switched to
ipratropium/albuterol (DuoNeb®) nebulization solution.
Atrovent® metered dose inhalers (MDIs) are not available for inpatient use at UPHSM. Non-ventilated patients
may be switched to umeclidinium inhalation or ipratropium (Atrovent®) nebulization solution. Ventilated
patients may be switched to ipratropium (Atrovent®) nebulization solution.
Tudorza® and Spiriva® inhalers may be switched to umeclidinium (Incruse®).
Document created: 08/11.
Revised: 01/17.
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Insulin Analogs
Generic Name Brand Name Dose Equivalents
Insulin lispro 75/25 mix Humalog 75/25® 0.5 to 1 units/kg/day in divided doses
Insulin aspart 70/30 mix Novolog 70/30® 0.5 to 1 units/kg/day in divided doses
Insulin glargine Lantus® Initial dose of 0.2 units/kg (10 units) once daily
Insulin detemir Levemir® Initial dose of 0.2 units/kg (10 units) once daily
*Formulary agent in bold (detemir preferred).
Notes:
When changing therapy in patients receiving basal insulin with insulin detemir once-daily to insulin glargine, a
1:1 conversion is recommended. However, for patients receiving basal dosing two or more times per day, a
20% reduction in the total daily basal dose is recommended for conversion to the insulin glargine dose.
Document created: 02/08.
Revised: 04/13.
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Intravenous to Oral
Generic Name IV Dosage Oral Dosage
Azithromycin 500 mg every 24 hours 500 mg every 24 hours
Cefazolin 1 gm every 8 hours Cephalexin 500 mg every 6 hours
Ciprofloxacin 400 mg every 12 hours 500-750 mg every 12 hours
Famotidine 20 mg every 12 hours 20 mg every 12 hours
Fluconazole 400 mg every 24 hours 400 mg every 24 hours
Levofloxacin 500 mg every 24 hours 500 mg every 24 hours
Levothyroxine 50 mcg every 24 hours 100 mcg every 24 hours
Linezolid 600 mg every 12 hours 600 mg every 12 hours
Metronidazole 500 mg every 6 hours 500 mg every 6 hours
Ondansetron 4-8 mg 8-16 mg
Pantoprazole 40 mg every 24 hours Omeprazole 20 mg every 24 hours
Rifampin 300 mg every 12 hours 300 mg every 12 hours
Valproic acid 500 mg every 6 hours 500 mg every 6 hours
Voriconazole
LD: 6 mg/kg every 12 hours x2;
MD: 4 mg/kg every 12 hours
Pt wt ≥40 kg: 200 mg every 12 hours
Pt wt ≤40 kg: 100 mg every 12 hours
Notes:
Situations where IV to PO conversion is appropriate:
q Patient is receiving/tolerating other oral medications;
q Patient is receiving regular diet and has not been designated ‘Nothing Per Os’ (NPO);
q Patient’s enteral route is functional [i.e., receiving enteral feedings without residuals or has evidence that
gastrointestinal (GI) tract is functional (i.e., no evidence of ileus or profuse diarrhea)];
q Patient does not have active GI bleeding;
q Patient has been afebrile for at least 24 hours (antibiotics only);
q Patient is not hypotensive (i.e., SBP < 90 mmHg) or on vasopressor support to maintain blood pressure;
q Patient does not have mucositis (for patients undergoing chemotherapy and who do not have a nasogastric
tube).
Recommendation for valproic acid conversion based on using immediate-release formulation of solution or
capsules.
Dosage for PO conversion of ciprofloxacin depends upon severity of infection.
Document created: 07/11.
Revised: 05/16.
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Leukotriene Receptor Antagonists
Generic Name Brand Name Dose Equivalents (mg/day)
Montelukast Singulair® 10
Zafirlukast Accolate® 40
*Formulary agent in bold.
Document created: 06/07.
Revised: 08/11.
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Levalbuterol
Generic Name Brand Name Dose Equivalents
Albuterol nebulization solution Generic 2.5 mg every 4 hours
Levalbuterol nebulization solution Xopenex® 0.63 mg to 1.25 mg every 4-6 hours
*Formulary agent in bold.
Generic Name Brand Name Dose Equivalents
Albuterol MDI Ventolin HFA® 1-2 inhalations every 4 hours
Levalbuterol MDI Xopenex HFA® 1-2 inhalations every 4-6 hours
*Formulary agent in bold.
Notes:
Levalbuterol orders with a PRN frequency will be interchanged with albuterol orders with a PRN frequency.
Albuterol nebulization solution contains albuterol 2.5 mg in each 3 mL unit-dose vial (0.083%).
Levalbuterol HFA contains 45 mcg per actuation
Albuterol HFA contains 90 mcg per actuation
The automatic therapeutic interchange for levalbuterol is approved for inpatients 12 years of age and older
unless appropriate documentation is provided for levalbuterol use (see guidelines for use).
Document created: 03/08.
Revised: 12/13.
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Miscellaneous Antidepressants
Generic Name Brand Name
Venlafaxine, extended release Effexor XR® 75 150 N/A
Desvenlafaxine Pristiq® 50 100 N/A
*Formulary agents in bold.
Notes:
Desvenlafaxine is the major active metabolite of venlafaxine.
Dose Equivalents (mg/day)
In clinical studies, desvenlafaxine dosages of 50 to 400 mg/day were shown to be effective, although no
additional benefit was demonstrated at dosages of more than 50 mg/day. Adverse reactions and
discontinuations were more frequent at higher doses.
Document created: 08/11.
Revised: 05/16.
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Miscellaneous CNS Stimulants
Generic Name Brand Name Dose Equivalents
Armodafinil Nuvigil® 150 to 250 mg once daily in the morning
Modafinil Provigil® 200 to 400 mg once daily in the morning
*Formulary agent in bold.
Document created: 05/16.
Revised: None
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Nitroglycerin Sublingual
Generic Name Brand Name Dose Equivalents
Nitroglycerin 0.4 mg/actuation
spray Nitrolingual®
1 to 2 sprays every 5 minutes for a maximum of 3
sprays in 15 minutes
Nitroglycerin 0.4 mg tablet NitroStat®
0.4 mg every 5 minutes for a maximum of 3 tablets in
15 minutes
*Formulary agent in bold.
Notes:
Nitroglycerin spray will be maintained on formulary as a uterine relaxant; however, for the management of
angina, it will be interchanged with nitroglycerin sublingual tablets.
Document created: 05/16.
Revised: None
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Non-benzodiazepine Hypnotics
Generic Name Brand Name
Zolpidem Ambien® N/A 5 10 N/A
Eszopiclone Lunesta® 1 2 N/A 3
Zaleplon Sonata® N/A 5 10 20
Zolpidem, extended release Ambien CR® N/A 6.25 12.5 N/A
*Formulary agent in bold.
Dose Equivalents (mg/day)
Document created: 11/05.
Revised: 08/11.
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Non-sedating Antihistamines
Generic Name Brand Name
Loratadine Claritin® 5 10 10
Cetirizine Zyrtec® 2.5 5 10
Desloratadine Clarinex® N/A 5 5
Fexofenadine Allegra® 60 120 180
*Formulary agent in bold.
Notes:
Dose Equivalents (mg/day)
Patients receiving decongestant/antihistamine combination products (i.e., Allegra-D 12 and 24 hour, Claritin-
D, and Zyrtec-D) will be converted to loratadine and pseudoephedrine individually.
Document created: 08/05.
Revised: 08/11.
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Ophthalmic Preparations
Generic Name Brand Name Dose Equivalents
Latanoprost Xalatan® 1 drop into affected eye(s) once daily in the evening
Bimatoprost Lumigan® 1 drop into affected eye(s) once daily in the evening
Travoprost Travatan® 1 drop into affected eye(s) once daily in the evening
*Formulary agent in bold.
Generic Name Brand Name Dose Equivalents
Dorzolamide Trusopt® 1 drop into affected eye(s) three times daily
Brinzolamide Azopt® 1 drop into affected eye(s) three times daily
*Formulary agent in bold.
Generic Name Brand Name Dose Equivalents
Timolol Timoptic® 1 drop into affected eye(s) twice daily
Betaxolol Betoptic-S® 1 to 2 drops into affected eye(s) twice daily
Carteolol Ocupress® 1 drop into affected eye(s) twice daily
Levobunolol Betagan® 1 to 2 drops into affected eye(s) twice daily
Metipranolol Optipranolol® 1 drop into affected eye(s) twice daily
*Formulary agent in bold.
Notes:
Betaxolol is available in 0.25% and 0.5% solutions.
Carteolol is available in a 1% solution.
Levobunolol is available in 0.25% and 0.5% solutions.
Metipranolol is available in a 0.3% solution.
Initial dose for timolol is 0.25%, 1 drop into affected eye(s). Timoptic® is usually dosed twice daily; Timoptic-
XE® is usually dosed once daily. If clinical response is not adequate, the dosage may be changed to the 0.5%
solution.
Document created: 08/11.
Revised: None
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Phosphate Binders
Generic Name Brand Name
Calcium acetate PhosLo® 667 1334 2001 2668
Sevelamer hydrochloride Renagel® 800 1600 2400 3200
Sevelamer carbonate Renvela® 800 1600 2400 3200
Lanthanum Fosrenol® 250 500 750 1000
*Formulary agents in bold.
Notes:
Calcium acetate is available in 667 mg tablets.
Dose Equivalents (mg/meal)
Document created: 05/06.
Revised: 01/13.
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: Proton Pump Inhibitors
Generic Name Brand Name
Omeprazole, oral Prilosec® 20 40
Dexlansoprazole Kapidex® 30 60
Esomeprazole Nexium® 20 40
Lansoprazole Prevacid® 15 30
Pantoprazole Protonix® 20 40
Rabeprazole Aciphex® 20 20
Pantoprazole, injection Protonix IV® 40 80
Esomeprazole Nexium IV® 40 80
*Formulary agents in bold.
Dose Equivalents (mg/day)
By declaration of the P&T Committee, the Proton Pump Inhibitors are subject to automatic IV to PO
interchange. Please refer to the Intravenous to Oral Medication Conversion Program for further details.
Document created: 03/02.
Revised: 08/11.
Upper Peninsula Health System - Marquette
Pharmacy and Therapeutics Committee-approved
Therapeutic Interchange: HMG CoA Reductase Inhibitors (Statins)
Generic Name Brand Name
Atorvastatin Lipitor® 10 20 40 80
Pravastatin Pravacol® 40 80 N/A N/A
Rosuvastatin Crestor® 5 10 20 40
Simvastatin Zocor® 20 40 80 N/A
Fluvastatin Lescol® 80 N/A N/A N/A
Lovastatin Mevacor® 40 80 N/A N/A
Pitavastatin Livalo® 2 4 N/A N/A
*Formulary agents in bold.
Notes:
Simvastatin is the preferred therapeutic substitution for lovastatin.
Dose Equivalents (mg/day)
Due to the increased risk of myopathy, including rhabdomyolysis, use of simvastatin 80 mg daily should be
restricted to patients who have been taking simvastatin 80 mg per day chronically (i.e., 12 months or longer)
without evidence of muscle toxicity.
Document created: 08/11.
Revised: None